Travere Therapeutics (TVTX) CMO logs PSU vesting and routine share sales
Rhea-AI Filing Summary
Travere Therapeutics’ chief medical officer Jula Inrig reported a mix of equity award vesting and routine share sales. On April 13, 2026, 14,000 shares of common stock were acquired at no cost upon the vesting of performance restricted stock units tied to FDA approval of FILSPARI (sparsentan) in FSGS.
On April 14, 2026, Inrig sold 7,215 shares of common stock at an average price of $41.9288 per share in open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on May 28, 2025. On April 15, 2026, a further 1,018 shares were sold at $42.61 per share to cover tax withholding obligations related to the PSU settlement, as required by the company’s equity incentive plans. Following these transactions, Inrig held 111,473 shares of Travere Therapeutics common stock directly.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Buyer: 5,767 shares
Net Buy
3 txns
Insider
Inrig Jula
Role
CHIEF MEDICAL OFFICER
Sold
8,233 shs ($346K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,018 | $42.61 | $43K |
| Sale | Common Stock | 7,215 | $41.9288 | $303K |
| Grant/Award | Common Stock | 14,000 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 111,473 shares (Direct)
Footnotes (3)
- F1. On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS.
- F2. Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
- F3. This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
Key Figures
PSU vesting shares: 14,000 shares
Open-market sale 1: 7,215 shares at $41.9288/share
Open-market sale 2: 1,018 shares at $42.61/share
+3 more
6 metrics
PSU vesting shares
14,000 shares
Performance restricted stock units vested on April 13, 2026
Open-market sale 1
7,215 shares at $41.9288/share
Common stock sold on April 14, 2026
Open-market sale 2
1,018 shares at $42.61/share
Common stock sold on April 15, 2026 to cover taxes
Net shares sold
8,233 shares
Net sell shares across reported sales
Post-transaction holdings
111,473 shares
Direct common stock held after April 15, 2026
PSU grant date
January 31, 2025
Date performance restricted stock units were originally granted
Key Terms
performance restricted stock units (PSUs), sell to cover, Rule 10b5-1(c), tax withholding obligation, +2 more
6 terms
performance restricted stock units (PSUs) financial
"the reporting person was granted performance restricted stock units (PSUs) which PSUs vested"
sell to cover financial
"require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction"
Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.
Rule 10b5-1(c) regulatory
"written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
tax withholding obligation financial
"shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement"
equity incentive plans financial
"mandated by the Issuer's election under its equity incentive plans to require the Reporting Person"
Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.
FILSPARI (sparsentan) technical
"FDA had granted approval of FILSPARI (sparsentan) in FSGS"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Travere Therapeutics (TVTX) report for Jula Inrig?
Travere Therapeutics reported that chief medical officer Jula Inrig received 14,000 shares from vested performance restricted stock units, then sold 7,215 and 1,018 shares in open-market transactions around $42 per share, largely related to tax and pre-arranged trading activity.
What triggered the vesting of Jula Inrig’s performance stock units in Travere Therapeutics (TVTX)?
The performance restricted stock units vested when the U.S. Food and Drug Administration approved FILSPARI (sparsentan) for FSGS, as confirmed by Travere Therapeutics on April 13, 2026. This milestone led to the issuance of 14,000 common shares to Jula Inrig at no purchase price.